Jishuai Zhang
Shenzhen, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Anti-BCMA CAR T-cell for IgG4-related disease: is this necessary? - Authors' reply.
Journal: The Lancet. Rheumatology
Published: January 03, 2026
BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis.
Journal: Annals of the rheumatic diseases
Published: March 24, 2025
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma.
Journal: Lancet (London, England)
Published: March 19, 2025
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies.
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies.
Journal: Experimental hematology & oncology
Published: July 10, 2024
Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma.
Journal: Frontiers in immunology
Published: May 22, 2024
Single VHH-directed BCMA CAR-NK cells for multiple myeloma.
Journal: Experimental hematology & oncology
Published: November 06, 2023
Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph+ B cell acute lymphoblastic leukemia.
Journal: Frontiers in immunology
Published: June 10, 2022
Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies.
Journal: Cancer biology & medicine
Published: August 14, 2021
Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus.
Journal: Journal for immunotherapy of cancer
Published: July 02, 2020
Showing 1-12 of 12
Last Updated: 09/26/2026